Tenax Therapeutics, Inc. (NASDAQ:TENX) Files An 8-K Submission of Matters to a Vote of Security Holders

Tenax Therapeutics, Inc. (NASDAQ:TENX) Files An 8-K Submission of Matters to a Vote of Security Holders
Item 5.07 Submission of Matters to a Vote of Security Holders.

Tenax Therapeutics, Inc. (the “Company”) held its Annual Meeting of Stockholders on June 13, 2018 (the “Annual Meeting”). The stockholders considered the two proposals described below, each of which is described in more detail in the Company’s definitive proxy statement dated April 20, 2018 (the “Proxy Statement”). As of April 16, 2018, the record date for the Annual Meeting, there were 1,453,637 shares of common stock issued, outstanding and entitled to vote. At the Annual Meeting, 1,123,016 shares of common stock were represented in person or by proxy, constituting a quorum. The final number of votes cast for and against, as well as the number of abstentions and broker non-votes, with respect to each proposal are set forth below.

Proposal 1: To elect the six director nominees described in the Proxy Statement to the Company’s Board of Directors to serve until the sooner of the next Annual Meeting of the Company’s Stockholders or the election and qualification of their successors. The votes were cast as follows:

Ronald R. Blanck, DO

158,112

119,441

845,463.00

Anthony A. DiTonno

270,390

7,163

845,463.00

James Mitchum

270,362

7,191

845,463.00

Gregory Pepin

157,891

119,662

845,463.00

Gerald T. Proehl

269,206

8,347

845,463.00

Chris A. Rallis

270,552

7,001

845,463.00

All director nominees were duly elected.

Proposal 2: To ratify the appointment of Cherry Bekaert LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2018. The votes were cast as follows:

For

Against

Abstain

965,452

145,956

11,608

Proposal 2 was approved.


About Tenax Therapeutics, Inc. (NASDAQ:TENX)

Tenax Therapeutics, Inc. is a specialty pharmaceutical company. The Company is focused on identifying, developing and commercializing products for the critical care market. The Company’s main product is levosimendan. Levosimendan is a calcium sensitizer developed for intravenous use in hospitalized patients with acutely decompensated heart failure. Levosimendan represents therapeutic modalities for the treatment of Low Cardiac Output Syndrome (LCOS), septic shock and other critical care conditions. The therapeutic effects of levosimendan are mediated through increased cardiac contractility by calcium sensitization of troponin C, resulting in a positive inotropic effect, which is not associated with substantial increases in oxygen demand; opening of potassium channels in the vasculature smooth muscle, resulting in a vasodilatory effect on all vascular beds, and opening of mitochondrial potassium channels in cardiomyocytes, resulting in a cardioprotective effect.

An ad to help with our costs